Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
about
Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatinPediatric Statin Administration: Navigating a Frontier with Limited DataThe effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjectsRhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarinAdherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy--a nationwide register studyClinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.Metabolism-based drug interactions involving oral azole antifungals in humans.Drug interactions and the statins.Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.Cerivastatin: the low-dose HMG-COA reductase inhibitor.Interaction of common azole antifungals with P glycoproteinElderly patients at risk for coronary heart disease or stroke: selecting an ideal product for lipid lowering.Weight gain and cardiovascular risk after organ transplantation.The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins.Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions.Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin.Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells.Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know."Cocktail" approaches and strategies in drug development: valuable tool or flawed science?Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugsCYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungalsDifferent effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatinPharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin.Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects.Suboptimal choices and dosing of statins at start of therapyPharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.In vivo information-guided prediction approach for assessing the risks of drug-drug interactions associated with circulating inhibitory metabolitesDrug-drug interactions of antifungal agents and implications for patient care.Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.Lipid-lowering effects of statins: a comparative review.Role of P-glycoprotein in statin drug interactions.Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis.Simvastatin: present and future perspectives.Pitavastatin: efficacy and safety in intensive lipid lowering.Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.
P2860
Q24679132-970DC71E-C999-4C37-B6C6-9484D99771A4Q28068014-DFF0A06E-6941-43D0-B490-33034E403735Q28361017-E8D6031A-197F-4B61-96B5-3D82D1D21177Q28378361-B2FD10EA-B8F9-42DF-94FC-0F05FC9FF2FDQ28535157-691AF35B-8E66-4F44-897A-B317930B6B81Q30234940-3B5F02B5-3FE7-479C-B3F6-97292F15B84DQ33719828-29FBA36A-7E33-4B79-A24B-7F2D36FACA3AQ33786019-EF44D3C1-E0BD-4A2C-B428-284F3B08EC58Q33983600-D3371F19-282F-4393-9BAF-92E3796A30D5Q34074683-92FFCEE2-3158-4E69-8A6C-B0F27EFA5D23Q34104641-7A8F4506-5EAC-493F-8EE1-D2FDDA2C0EADQ34186428-908D981B-50E3-4C02-B18E-959AEC3F5F16Q34239244-45BEA0AA-5BB0-46F9-BFDF-4FAB4180D41FQ34388588-0E9B9261-F4A1-4607-905D-2F06B8EAFE12Q34389584-869E8C18-18E7-4F27-9CEF-659B23D3B7C0Q34448305-90E20334-3844-44B8-B684-F8D7EEA76519Q34474583-3FFFEAAC-27DB-4A12-B8D0-9D68D7CCCB3CQ34773911-625B89DA-1827-4095-B811-2D6FC392E371Q35028546-C3E84046-EA65-4A32-B4D8-4214AEEFE9E5Q35608207-294460E9-36FC-4611-ADF5-E8469BBA1C00Q35640730-E5C48224-E497-4BA9-9A5B-BD9053B389C6Q35642257-3E58D9BE-69FF-48A9-9D83-E407D4BEAAF5Q35718619-9754ABEB-014A-49F4-9272-842C89D12E56Q35776638-D323936E-B2C1-41C8-8EC2-B0322C7E1921Q35803083-5CD764CC-16E0-40A2-802B-C8F05CAE1625Q35804027-9B80BF45-1EC1-425E-B658-FC1F7F287B2AQ35825922-BFD46266-46D1-463D-9A5E-DB332E958034Q35827103-435238F0-1547-4398-B6BE-7F74B9A83167Q35827696-D17CA9F3-891C-49DE-855F-3632DD816B4FQ36105348-1D12A8BC-8240-45A4-AA28-A7048F7B138BQ36283721-1AEBD3DE-C001-438C-A0F2-2EC7F9783DF9Q36369136-ADB4097A-6701-4655-9A06-FF803DFDB69DQ36573878-495A5D62-B33F-47AF-9F33-5E95657E5687Q36634221-499245F7-C200-4205-BB77-D8BAF222F334Q36687277-F345C144-365D-40CD-93D2-402A514AB861Q36817063-56DE5CE8-B5AA-47A9-AE6E-B6766A8C855CQ36916934-693F76A1-E4FD-4E0A-8124-28A6369C4C2EQ36967274-A33E8020-B17F-4754-8D23-2C4521652B2DQ36986507-E9D6E9B8-BDA1-4C31-95CE-B292B23ACBE5Q37399440-8E40F21B-D5BD-4E32-A090-FF905E539C95
P2860
Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Simvastatin but not pravastati ...... CYP3A4 inhibitor itraconazole.
@en
Simvastatin but not pravastati ...... CYP3A4 inhibitor itraconazole.
@nl
type
label
Simvastatin but not pravastati ...... CYP3A4 inhibitor itraconazole.
@en
Simvastatin but not pravastati ...... CYP3A4 inhibitor itraconazole.
@nl
prefLabel
Simvastatin but not pravastati ...... CYP3A4 inhibitor itraconazole.
@en
Simvastatin but not pravastati ...... CYP3A4 inhibitor itraconazole.
@nl
P2093
P1476
Simvastatin but not pravastati ...... CYP3A4 inhibitor itraconazole.
@en
P2093
Kivistö KT
Neuvonen PJ
P304
P356
10.1016/S0009-9236(98)90165-5
P407
P577
1998-03-01T00:00:00Z